Dominic Johnson, MD
Interventional Cardiology · Greenville, SCNPI 1720308851
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,991 of the $12,793 with a category attached, or 62.5%. 36 manufacturers reported payments, led by Abbott at 41.5% of the total. Reporting peaked in 2021 at $3,176 and has fallen 50.9% since, to $1,560 in 2025.
Across 352 payments — averaging $36.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Boston Scientific$2K
- Abiomed$669
- Medtronic$656
- Amgen$566
- Novartis$459
- plus $3K from 30 others
What the payments were for
- Consulting fees$9387%
- Speaking & faculty fees$2,40019%
- Travel & lodging$1,38411%
- Food & beverage$7,99162%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 81 | $5,313 |
| Boston Scientific | 37 | $2,449 |
| Abiomed | 17 | $669 |
| Medtronic(2 entities) | 45 | $656 |
| Amgen | 17 | $566 |
| Novartis | 24 | $459 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $360 |
| Cardiovascular Systems Inc. | 24 | $316 |
| Edwards Lifesciences | 5 | $264 |
| Shockwave Medical, Inc | 13 | $252 |
| E.r. Squibb & Sons, L.L.C. | 11 | $185 |
| Inari Medical, Inc. | 1 | $182 |
| Philips North America LLC | 7 | $169 |
| Boehringer Ingelheim | 8 | $138 |
| AstraZeneca | 9 | $137 |
| Pfizer | 6 | $90 |
| Johnson & Johnson | 5 | $82 |
| Astellas Pharma US Inc | 1 | $80 |
| Merck | 3 | $50 |
| Atricure, Inc. | 2 | $42 |
| Biosense Webster, Inc. | 1 | $38 |
| Acist Medical Systems, Inc. | 1 | $36 |
| Portola Pharmaceuticals, LLC | 1 | $32 |
| Cardiva Medical, Inc. | 2 | $28 |
| Bayer | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Livanova USA, Inc. | 1 | $21 |
| Cvrx, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Penumbra, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Terumo Medical Corporation | 1 | $12 |
| Baylis Medical Company Inc | 1 | $12 |
| Cardinal Health 200 LLC | 1 | $11 |
| ZOLL Medical Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dragonfly OCT$2,400
- Watchman$1,091
- Perclose ProGlide suture mediated closure system$1,045
- GENERAL VASCULAR ACCESS$551
- Impella$409
- FLOWTRIEVER CATHETER, S$365
- CARDIOMEMS$202
- Diamondback Coronary$167
- MitraClip$164
- WATCHMAN FLX$145
- TRICLIP$133
- CROSSBOSS$120
- Farapulse$119
- Edwards SAPIEN 3 Transcatheter Heart Valve$119
- LifeVest$112
How this compares
$12,793 in reported general payments places this provider in the 60th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 242 | $217,163 |
| EntrestoSacubitril/Valsartan | 115 | $118,560 |
| Repatha SureclickEvolocumab | 48 | $54,590 |
| XareltoRivaroxaban | 34 | $39,115 |
| JardianceEmpagliflozin | 36 | $36,471 |
| BrilintaTicagrelor | 27 | $13,482 |
| Praluent PenAlirocumab | 15 | $10,539 |
| Repatha PushtronexEvolocumab | 13 | $7,401 |
| Ranolazine ErRanolazine | 38 | $4,091 |
| Metoprolol Succinate | 279 | $3,245 |
| Atorvastatin Calcium | 246 | $2,545 |
| Rosuvastatin Calcium | 72 | $1,819 |
| ClopidogrelClopidogrel Bisulfate | 164 | $1,817 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 203 | $1,623 |
| Prasugrel Hcl | 14 | $1,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $90 | $217,163242 claims |
| NovartisEntresto | $459 | $118,560115 claims |
| Johnson & JohnsonXarelto | $82 | $39,11534 claims |
| Boehringer IngelheimJardiance | $138 | $36,47136 claims |
| AstraZenecaBrilinta | $137 | $13,48227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Greenville
- Jesse JorgensenGreenville$102K
- Josh DollGreenville$79K
- Chetan PatelGreenville$21K
- Daniel GreenGreenville$13K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
- Nicholas AmorosoPawleys Island$283K
- Robert LeonardiWest Columbia$203K
- Anbukarasi MaranCharleston$132K
- Thomas TodoranPawleys Island$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.